The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.
 
Frank Yung-Chin Tsai
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Aptitude Health; Aptitude Health; Aptitude Health; Tempus
Research Funding - Flynn Foundation (Inst); PhRma Foundation (Inst)
Patents, Royalties, Other Intellectual Property - Clinical trial software.
 
Michael J. Birrer
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck
 
Jason R Brown
Honoraria - AstraZeneca
Speakers' Bureau - EMD Serono
Research Funding - Bicycle Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Seagen (Inst)
 
Sanjay Chandrasekaran
Stock and Other Ownership Interests - Lilly
 
Vincent Chung
Consulting or Advisory Role - Perthera
Speakers' Bureau - AstraZeneca; Coherus Biosciences; Ipsen
Research Funding - Merck (Inst)
 
Richard C. Frank
No Relationships to Disclose
 
Edward Graeme Garmey
Employment - CMO Consulting, INC.
Consulting or Advisory Role - Circle Pharma; GigaGen ; ImmuneSensor Therapeutics; ModeX Therapeutics; Novita Pharmaceuticals
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - AstraZeneca
 
Thomas J. George
Consulting or Advisory Role - Avammune Therapeutics; BillionToOne; KAHR Medical; Nihon Medi-Physics; Seagen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BillionToOne (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst)
 
Shadia Ibrahim Jalal
Research Funding - Astex Pharmaceuticals; AstraZeneca/MedImmune; Tesaro
 
Andrew Stewart Poklepovic
Consulting or Advisory Role - Novartis
Speakers' Bureau - Natera
 
Jennifer Margaret Segar
No Relationships to Disclose
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Jue Jillian Zhang
Employment - Novita Pharmaceuticals
Leadership - Novita Pharmaceuticals
Stock and Other Ownership Interests - Novita Pharmaceuticals
Consulting or Advisory Role - Novita Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - Novita Pharmaceuticals (I)
 
Anup Kasi
Consulting or Advisory Role - Cardinal Health; Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)